-

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

  • BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada
  • Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida.

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. Replays will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Akinc
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276

Industry:

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY
Release Versions
English

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Akinc
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276

More News From Alnylam Pharmaceuticals, Inc.

Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth. "Today we announced two important decisions, both of which demonstrate our conviction in Alnylam's future," said Amy Schulman, Chair of Alnylam's Board of Directors. "Alnylam ha...

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London. A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours a...

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi...
Back to Newsroom